Conti Investment Edge Therapeutics Announces IPO
30, Sep, 2015
Edge Therapeutics, Inc. (Nasdaq:EDGE), one of The Conti Group’s Corporate Investments and a company on which Conti’s CEO Kurt Conti sits as a board member, has announced its initial public offering (IPO). The 7,315,151 shares of its commons stock are valued at a public offering price of $11.00 per share, before underwriting discounts and commissions. In addition, Edge Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,097,272 shares of common stock at the same price to cover over-allotments, if any.
Edge Therapeutics was founded in 2009 and has since built itself into a leading developer of hospital-based therapies to treat and manage acute, life-threatening neurological and other conditions. Having served on the board since 2010, Kurt Conti has provided consultation and direction to the core Edge team.
Speaking on the announcement, he said, “I am proud to be part of a business venture that has grown so quickly and successfully while maintaining high quality standards in biotechnology development.”